Therapeutic effect of silymarin.
Conditions
Interventions
Intervention 1: Intervention group: Silymarin tablets, 140 mg, 3 times a day, for 6 months, orally. Intervention 2: Control group: Placebo tablets, 140 mg, 3 times a day, for 6 months, orally.
Treatment - Drugs
Intervention group: Silymarin tablets, 140 mg, 3 times a day, for 6 months, orally
Control group: Placebo tablets, 140 mg, 3 times a day, for 6 months, orally
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: People with multiple sclerosis who go to Kashani hospital in Isfahan. Patients taking CinnoVex for less than 1 year.
Exclusion criteria
Exclusion criteria: Patients with multiple sclerosis treated with other interferon beta drugs and immunosuppressive drugs Patients who have already received CinnoVex and their treatment has been discontinued
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum interleukin level 10. Timepoint: 2 months before the intervention, 6 months after the intervention. Method of measurement: ELISA.;Serum interleukin level 17. Timepoint: 2 months before the intervention, 6 months after the intervention. Method of measurement: ELISA.;Serum interleukin level 23. Timepoint: 2 months before the intervention, 6 months after the intervention. Method of measurement: ELISA.;Serum interleukin level 35. Timepoint: 2 months before the intervention, 6 months after the intervention. Method of measurement: ELISA.;Serum interferon gamma. Timepoint: 2 months before the intervention, 6 months after the intervention. Method of measurement: ELISA.;Serum level of tumor growth factor beta. Timepoint: 2 months before the intervention, 6 months after the intervention. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactVahid Shaygannejad
Esfahan University of Medical Sciences
Outcome results
None listed